A Contrarian Opportunity in Beiersdorf Shares

Beiersdorf doubles venture capital to €100M for skin care innovation, betting on biotech and AI amid weak Nivea demand and a discounted stock valuation.

Despite a share price decline of approximately 20% since the start of the year, significantly underperforming the broader sector, Beiersdorf is making a decisive strategic move. The company has launched a new corporate venture capital fund with a volume of €100 million, doubling the size of its predecessor program from 2020.

Solid Fundamentals Amid Market Pessimism

The fundamental picture for the consumer goods giant remains robust. For the 2025 fiscal year, Beiersdorf generated revenue of €9.9 billion, increased group profit to €955 million, and has proposed a dividend of €1.00 per share. The ex-dividend date is scheduled for April 24.

However, the operational outlook is currently clouded. The recent stock weakness was triggered by the company's forecast for 2026, which projects flat to slightly positive organic sales growth and an EBIT margin slightly below the previous year's level of 14%. This guidance is pressured by weak demand for the Nivea brand, logistics challenges in the United States, and subdued travel retail business in China. The luxury brand La Prairie is facing particular headwinds, with analysts at UBS anticipating sales declines of around 20% for that segment.

A Strategic Bet on Innovation

In a clear signal of its long-term focus, Beiersdorf's newly established Skin Care Innovation Fund will invest globally in companies from early to growth stages, with initial investments ranging from €0.5 to €5 million. The fund's priorities are Life Sciences, biotechnology, AI-powered technologies, and sustainable solutions.

Initial portfolio companies include Vincere Biosciences, which researches mitophagy to slow skin aging, and Turbine, a specialist in AI-based cell simulation. In the sustainability arena, capital is flowing into DePoly's PET recycling technology and the precision-fermented lipid research of Melt&Marble. Since 2020, Beiersdorf has built a portfolio of more than 15 companies. One example of its integrated approach is the Belgian firm S-Biomedic, whose microbiome technology has been fully incorporated into Beiersdorf's product development pipeline.

Valuation Gap Attracts Analyst Attention

Interestingly, UBS recently upgraded its rating on Beiersdorf shares. This move was not based on an improved business dynamic but rather on valuation grounds. The stock currently trades at around 17 times estimated 2026 earnings, which is roughly 20% below the European sector average and far beneath Beiersdorf's own 10-year average price-to-earnings ratio of 27.

Upcoming Quarterly Report in Focus

The next key test for the company will be its quarterly statement for the first quarter of 2026, scheduled for release on April 21. Morgan Stanley anticipates a particularly weak start to the year for the Consumer segment, potentially worse than the already muted full-year forecast. Should the report align with these expectations, pressure on management is likely to intensify, compelling them to outline concrete measures for reigniting growth. The new innovation fund alone is unlikely to suffice in addressing these near-term challenges.